Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy
Cancer - United States
doi 10.1002/cncr.32522
Full Text
Open PDFAbstract
Available in full text
Date
October 4, 2019
Authors
Publisher
Wiley